摘要
目的 探讨安罗替尼联合免疫检查点抑制剂(ICI)二线及以上治疗驱动基因阴性晚期非小细胞肺癌的疗效和安全性。方法 依据治疗方式的不同将68例驱动基因阴性晚期非小细胞肺癌患者分为对照组和观察组,每组34例,对照组患者给予ICI(替雷利珠单抗)二线及以上治疗,观察组患者给予安罗替尼联合替雷利珠单抗二线及以上治疗。比较两组患者的临床疗效、肿瘤标志物[癌胚抗原(CEA)、血管内皮生长因子(VEGF)]水平及不良反应发生情况。结果 观察组患者的客观缓解率为82.35%,明显高于对照组患者的38.24%(P﹤0.01),疾病控制率为91.18%,明显高于对照组患者的50.00%(P﹤0.01)。治疗后,两组患者CEA、VEGF水平均低于本组治疗前,观察组患者CEA、VEGF水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为23.53%,与对照组患者的26.47%比较,差异无统计学意义(P﹥0.05)。结论 安罗替尼联合ICI二线及以上治疗驱动基因阴性晚期非小细胞肺癌患者,可提高临床疗效,降低肿瘤标志物水平,且不增加不良反应。
Objective To investigate the efficacy and safety of anlotinib combined with immune checkpoint inhibitor(ICI)second-line and above in the treatment of driver gene negative advanced non-small cell lung cancer.Method A to-tal of 68 patients with negative driver gene advanced non-small cell lung cancer were divided into control group and ob-servation group based on different treatment methods,with 34 cases in each group.The control group received ICI(tisleli-zumab)second-line or above treatment,while the observation group received anlotinib combined with tislelizumab sec-ond-line and above treatment.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),vascular endotheli-al growth factor(VEGF)]levels,and incidence of adverse reactions were compared between two groups.Result The ob-jective response rate of the observation group was 82.35%,which was significantly higher than 38.24%of the control group(P<0.01),and the disease control rate in the observation group was 91.18%,which was significantly higher than 50.00%of the control group(P<0.01).After treatment,the CEA and VEGF levels in both groups were lower than those before treatment,the CEA and VEGF levels in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the observation group was 23.53%,which was not statistically significant compared to 26.47%in the control group(P>0.05).Conclusion Anlo-tinib combined with ICI second-line or above in the treatment of driver gene negative advanced non-small cell lung can-cer,which can improve disease control rate,reduce tumor marker levels,and not increase adverse reactions.
作者
李笑萍
王江涛
花小梅
LI Xiaoping;WANG Jiangtao;HUA Xiaomei(Department of Medical Oncology,General Hospital of Pingxiang Mining Group Co.,Ltd.,Pingxiang 337000,Jiangxi,China;Department of Radiation Oncology Therapy,General Hospital of Pingxiang Mining Group Co.,Ltd.,Pingxiang 337000,Jiangxi,China)
出处
《癌症进展》
2024年第6期644-647,共4页
Oncology Progress
基金
江西省卫生健康委科技计划项目(202311768)。
关键词
非小细胞肺癌
安罗替尼
免疫检查点抑制剂
不良反应
non-small cell lung cancer
anlotinib
immune checkpoint inhibitor
adverse reaction
